Sanofi will retain its insulin business, but will otherwise stop research and development in diabetes and cardiovascular drugs in order to focus on cancer immunotherapies and its biologic for asthma and allergies.
Sanofi will retain its insulin business, but will otherwise stop research and development in diabetes and cardiovascular drugs in order to focus on cancer immunotherapies and its biologic for asthma and allergies.
The announcement was made Monday by Paul Hudson, the company’s new chief executive officer, who said during a media call that “we as a company have probably done more than almost any other companies combined, to innovate and to transform lives in diabetes and cardiovascular. Now we need to be efficient and move our resources to areas of opportunity, unmet needs and to grow our pipeline.”
Lantus, the originator insulin glargine, is under pressure from follow-on competition, given the commercialization of Boehringer Ingelheim’s Basaglar, the first FDA-approved insulin glargine follow-on, which launched in 2016 after a lengthy patent litigation with Sanofi.
In addition, insulin as a whole has been in the center of a debate for more than a year about high drug prices. Lantus, along with Novolog and Humalog, have shown highly synchronized price increases, coinciding with some of the largest growth in drug costs. And patients have traveled to Capitol Hill to testify how the rising prices have forced them to skip doses or go without.
However, a company spokesman said Monday that Sanofi will retain a proposed biosimilar of insulin aspart (NovoLog) in its pipeline as a registration phase molecule. Data on SAR341402 was presented in 3 late-breaking poster presentations at the American Diabetes Association (ADA) 79th Scientific Sessions last June. While insulins are currently regulated as drugs and follow-ons in the US context, they will become regulated as biologics and biosimilars in March 2020.
The Wall Street Journal (WSJ) noted Monday that diabetes has been a key driver for Sanofi since 2004, when Aventis and Sanofi-Synthelabo merged. Aventis had launched Lantus 4 years prior. By 2004, it was already the most widely prescribed insulin in the country.
Lantus represents that largest share of Part D spending on insulin, according to an analysis by the Kaiser Family Foundation.
Sanofi is shifting to focus on immunotherapies in cancer treatment; the company will buy biotech Synthorx for $2.5 billion. Sanofi has fallen behind in the race to develop immunotherapies, according to the WSJ report.
In addition, it wants to focus on dupilumab (Dupixent), a drug for severe chronic rhinosinusitis with nasal polyposis, severe asthma, and moderate-to-severe atopic dermatitis. Sanofi thinks the drug could eventually generate $10 billion.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.